高级检索
当前位置: 首页 > 详情页

IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]First Peoples Hosp Yunnan Prov, Dept Hepatobiliary Surg, Kunming, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Affiliated Hosp, Kunming, Yunnan, Peoples R China [3]First Peoples Hosp Yunnan Prov, Dept Infect Dis, Kunming, Yunnan, Peoples R China [4]Kunming Childrens Hosp, Dept Neurosurg, Kunming, Yunnan, Peoples R China [5]DICAT Biomed Computat Ctr, Vancouver, BC, Canada
出处:
ISSN:

关键词: Hepatocellular carcinoma IL-21 Natural killer cells

摘要:
Hepatocellular carcinoma (HCC) is the most common liver malignancy with dismal prognosis and limited treatment options. Natural killer (NK) cells are critical components of antitumor immunity due to their capacity to eliminate MHC class I-deficient cells. To evaluate the function of NK cells in HCC patients, circulating CD3(-)CD56(+) NK cells were collected from HBV-associated HCC patients and healthy control individuals. Compared to NK cells from healthy controls, NK cells from HCC patients presented functional impairment, characterized by significantly reduced cytotoxicity, degranulation, and cytokine production. Exogenous IL-21 could reinvigorate NK cells from HCC patients, resulting in significantly increased levels of cytotoxicity, de granulation, and cytokine expression. However, IL-21-treated NK cells from HCC patients still presented lower response than IL-21-treated NK cells from healthy controls. IL-21 resulted in increased phosphorylation of both STAT1 and STAT3 in NK cells. Inhibition of STAT1, but not STAT3, significantly reduced IL-21-mediated reinvigoration of NK function. Together, this study demonstrated that NK cells in HBV-associated HCC patients presented functional impairments that could be reverted by IL-21 in a STAT1-mediated mechanism.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 药学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 药学
JCR分区:
出版当年[2018]版:
Q2 IMMUNOLOGY Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]First Peoples Hosp Yunnan Prov, Dept Hepatobiliary Surg, Kunming, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Affiliated Hosp, Kunming, Yunnan, Peoples R China
通讯作者:
通讯机构: [1]First Peoples Hosp Yunnan Prov, Dept Hepatobiliary Surg, Kunming, Yunnan, Peoples R China [2]Kunming Univ Sci & Technol, Affiliated Hosp, Kunming, Yunnan, Peoples R China [*1]Department of Hepatobiliary Surgery, The First People's Hospital of Yunnan Province, Kunming, Yunnan, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82490 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号